CN114181301B - 针对SARS-CoV-2的无ADE效应的中和抗体 - Google Patents

针对SARS-CoV-2的无ADE效应的中和抗体 Download PDF

Info

Publication number
CN114181301B
CN114181301B CN202010960985.8A CN202010960985A CN114181301B CN 114181301 B CN114181301 B CN 114181301B CN 202010960985 A CN202010960985 A CN 202010960985A CN 114181301 B CN114181301 B CN 114181301B
Authority
CN
China
Prior art keywords
antibody
seq
cov
sars
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010960985.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114181301A (zh
Inventor
王乔
陆路
周韵娇
刘泽众
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fudan University
Original Assignee
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudan University filed Critical Fudan University
Priority to CN202010960985.8A priority Critical patent/CN114181301B/zh
Priority to PCT/CN2021/112201 priority patent/WO2022052733A1/fr
Publication of CN114181301A publication Critical patent/CN114181301A/zh
Application granted granted Critical
Publication of CN114181301B publication Critical patent/CN114181301B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002Coronaviridae
    • C07K16/1003Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
CN202010960985.8A 2020-09-14 2020-09-14 针对SARS-CoV-2的无ADE效应的中和抗体 Active CN114181301B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202010960985.8A CN114181301B (zh) 2020-09-14 2020-09-14 针对SARS-CoV-2的无ADE效应的中和抗体
PCT/CN2021/112201 WO2022052733A1 (fr) 2020-09-14 2021-08-12 Anticorps neutralisant sans effet ade pour sars-cov-2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010960985.8A CN114181301B (zh) 2020-09-14 2020-09-14 针对SARS-CoV-2的无ADE效应的中和抗体

Publications (2)

Publication Number Publication Date
CN114181301A CN114181301A (zh) 2022-03-15
CN114181301B true CN114181301B (zh) 2023-04-28

Family

ID=80539013

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010960985.8A Active CN114181301B (zh) 2020-09-14 2020-09-14 针对SARS-CoV-2的无ADE效应的中和抗体

Country Status (2)

Country Link
CN (1) CN114181301B (fr)
WO (1) WO2022052733A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116983401A (zh) * 2023-06-29 2023-11-03 贝湾生物科技有限公司 基于sars1病毒的新冠加强免疫疫苗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086561A2 (fr) * 2005-02-08 2006-08-17 New York Blood Center Neutralisation d'anticorps monoclonaux contre le coronavirus associe au syndrome respiratoire aigu severe
CN111333722A (zh) * 2020-03-03 2020-06-26 江苏省疾病预防控制中心(江苏省公共卫生研究院) SARS-CoV-2抑制剂及其应用
CN111592594A (zh) * 2020-03-13 2020-08-28 北京大学 一种抗新型冠状病毒的单克隆抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1884303A (zh) * 2005-06-20 2006-12-27 中国医学科学院基础医学研究所 SARS-CoV病毒结构蛋白的融合蛋白及其高量表达与纯化和用途
CN111303280B (zh) * 2020-03-22 2022-01-07 中国人民解放军军事科学院军事医学研究院 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用
CN111423508A (zh) * 2020-03-31 2020-07-17 江苏省疾病预防控制中心(江苏省公共卫生研究院) 一种分离的抗病毒感染的SARS-CoV-2蛋白结合分子
CN111592595B (zh) * 2020-04-27 2021-02-19 南京医科大学 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用
CN111620946B (zh) * 2020-05-09 2020-12-22 江苏省疾病预防控制中心(江苏省公共卫生研究院) 分离的新型冠状病毒单克隆抗体或其抗原结合部分
CN111560070B (zh) * 2020-05-27 2021-10-01 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒np蛋白的抗体及其检测应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086561A2 (fr) * 2005-02-08 2006-08-17 New York Blood Center Neutralisation d'anticorps monoclonaux contre le coronavirus associe au syndrome respiratoire aigu severe
CN111333722A (zh) * 2020-03-03 2020-06-26 江苏省疾病预防控制中心(江苏省公共卫生研究院) SARS-CoV-2抑制剂及其应用
CN111592594A (zh) * 2020-03-13 2020-08-28 北京大学 一种抗新型冠状病毒的单克隆抗体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2;Chi X.Y.等;《Science》;20200807;第650-655页 *

Also Published As

Publication number Publication date
WO2022052733A1 (fr) 2022-03-17
CN114181301A (zh) 2022-03-15

Similar Documents

Publication Publication Date Title
ES2954629T3 (es) Anticuerpos contra SARS-CoV-2
WO2021185346A1 (fr) Anticorps anti-sras-cov-2 et leurs utilisations
TW202204397A (zh) 對冠狀病毒s蛋白質具特異性之化合物及其用途
WO2021203053A1 (fr) Immunothérapie ciblant une région conservée dans des coronavirus sras
CN116194476A (zh) 针对sars-cov-2的抗体和其使用方法
KR20120105543A (ko) 인간 사이토메갈로바이러스에 대한 결합 멤버
JP2024506315A (ja) コロナウイルスのスパイクタンパク質を標的とする抗体
WO2021207948A1 (fr) Anticorps dirigés contre le sars-cov-2 et leurs utilisations
TW202246315A (zh) 對冠狀病毒s蛋白具特異性之化合物及其用途
WO2017011414A1 (fr) Molécules bispécifiques comprenant un bras dirigé contre l'enveloppe du vih-1
CA3192706A1 (fr) Anticorps du coronavirus et leurs utilisations
CN106459186B (zh) 针对hiv-1 v1v2 env区域的广谱中和性单克隆抗体
US20230272048A1 (en) Hiv-1 antibodies
CN114181301B (zh) 针对SARS-CoV-2的无ADE效应的中和抗体
WO2022056712A1 (fr) Anticorps anti-sars-cov-2 et leurs utilisations
CN115315442B (zh) Sars-cov-2抗体及其应用
JP2014526886A (ja) マクロファージ遊走阻止因子(mif)とd−ドーパクロームトートメラーゼ(d−dt)に交差反応性がある抗体
WO2016054023A1 (fr) Anticorps anti-vih-1 et utilisations de ceux-ci (adcc et ab bispécifiques)
WO2021203397A1 (fr) Anticorps anti-sars-cov-2 et leurs utilisations
CN114502589A (zh) 与entpd2和cd73抗体的组合疗法
US12030927B2 (en) Antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2
WO2023039064A2 (fr) Anticorps largement neutralisants contre des virus de type sars
AU2023220851A1 (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
CN117736314A (zh) 针对SARS-CoV-2和其变异株的中和抗体及其用途
TW202405000A (zh) Sars-cov2抗體及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant